Reported Earlier, Spyre Therapeutics Prices $350M Public Offering Of 4,117,648 Common Shares At $85.00 Per Share, Plans To Fund Gastroenterology, Rheumatology And Dermatology Programs
Share
Why It Matters
Spyre Therapeutics raised 350 million dollars by selling company shares. The money will help them build new medicines for three different diseases.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.